{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T08:06:51Z","timestamp":1775030811654,"version":"3.50.1"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10147-025-02811-4","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T23:06:44Z","timestamp":1749251204000},"page":"1437-1438","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of belantamab mafodotin for multiple myeloma, asciminib for leukemia, osimertinib for lung cancer, amivantamab for lung cancer, and pembrolizumab for pleural mesothelioma in Japan"],"prefix":"10.1007","volume":"30","author":[{"given":"Noriomi","family":"Matsumura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Mandai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,7]]},"reference":[{"key":"2811_CR1","unstructured":"Pharmaceuticals and Medical Devices Agency (2025) List of approved drugs (in Japanese). https:\/\/www.pmda.go.jp\/review-services\/drug-reviews\/review-information\/p-drugs\/0010.html Accessed on June 1, 2025"},{"key":"2811_CR2","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa2405090","volume":"391","author":"V Hungria","year":"2024","unstructured":"Hungria V, Robak P, Hus M et al (2024) Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 391:393\u2013407. https:\/\/doi.org\/10.1056\/NEJMoa2405090","journal-title":"N Engl J Med"},{"key":"2811_CR3","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa2403407","volume":"391","author":"MA Dimopoulos","year":"2024","unstructured":"Dimopoulos MA, Beksac M, Pour L et al (2024) Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma. N Engl J Med 391:408\u2013421. https:\/\/doi.org\/10.1056\/NEJMoa2403407","journal-title":"N Engl J Med"},{"key":"2811_CR4","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMoa2400858","volume":"391","author":"A Hochhaus","year":"2024","unstructured":"Hochhaus A, Wang J, Kim DW et al (2024) Asciminib in newly diagnosed chronic myeloid leukemia. N Engl J Med 391:885\u2013898. https:\/\/doi.org\/10.1056\/NEJMoa2400858","journal-title":"N Engl J Med"},{"key":"2811_CR5","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMoa2402614","volume":"391","author":"S Lu","year":"2024","unstructured":"Lu S, Kato T, Dong X et al (2024) Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC. N Engl J Med 391:585\u2013597. https:\/\/doi.org\/10.1056\/NEJMoa2402614","journal-title":"N Engl J Med"},{"key":"2811_CR6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","volume":"35","author":"A Passaro","year":"2024","unstructured":"Passaro A, Wang J, Wang Y et al (2024) Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol 35:77\u201390. https:\/\/doi.org\/10.1016\/j.annonc.2023.10.117","journal-title":"Ann Oncol"},{"key":"2811_CR7","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1016\/S0140-6736(23)01613-6","volume":"402","author":"Q Chu","year":"2023","unstructured":"Chu Q, Perrone F, Greillier L et al (2023) Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. Lancet 402:2295\u20132306. https:\/\/doi.org\/10.1016\/S0140-6736(23)01613-6","journal-title":"Lancet"},{"key":"2811_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/cas.70082","author":"T Kijima","year":"2025","unstructured":"Kijima T, Kato T, Goto Y et al (2025) KEYNOTE-A17: first-line pembrolizumab plus cisplatin-pemetrexed in japanese participants with advanced pleural mesothelioma. Cancer Sci. https:\/\/doi.org\/10.1111\/cas.70082","journal-title":"Cancer Sci"},{"key":"2811_CR9","unstructured":"Pharmaceuticals and Medical Devices Agency (2025) Revisions of PRECAUTIONS (FY2025). https:\/\/www.pmda.go.jp\/english\/safety\/info-services\/drugs\/revision-of-precautions\/0013.html Accessed on June 1, 2025"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02811-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02811-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02811-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T07:37:18Z","timestamp":1753429038000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02811-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,7]]},"references-count":9,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2811"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02811-4","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,7]]},"assertion":[{"value":"7 June 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}